Normal, IL

Sneeze, Wheeze and Itch Associates

Allergic Rhinitis

Rhinitis

Seasonal Allergic Rhinitis

Perennial Allergic Rhinitis

Hypersensitivity

Asthma

Immediate Hypersensitivity

Atopic Dermatitis

Peanut Hypersensitivity

Cough

azelastine hydrochloride

fluticasone propionate

azelastineHcl

beclomethasone dipropionate

azelastine Hcl

BLU-5937

Omalizumab

QVAR

azelastine HCl

Asimadoline

Meda Pharmaceuticals

Teva Pharmaceuticals

Allergy Therapeutics

Bellus Health

COUR Pharmaceuticals

Novartis

Tioga Pharmaceuticals

condition

Chronic Cough

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Sneeze, Wheeze and Itch Associates | Normal, IL

Site insights

Active trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

Trial sponsors